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Abstract
Background: A critical need exists to better understand the physiological sequel of vitamin D supplementation in
obese individuals and African Americans. The aim was to comprehensively evaluate dose- and time-responses of a
panel of vitamin D biomarkers to vitamin D supplements in this population.
Methods: We conducted a 16-week randomized, double-blinded, and placebo-controlled clinical trial. Seventy
overweight/obese African Americans (age 13–45 years, 84 % females) with 25-hydroxyvitamin D [25(OH)D]
concentrations ≤20 ng/mL were randomly assigned to receive a supervised monthly oral vitamin D3 of 18,000 IU
(~600 IU/day, n = 17), 60,000 IU (~2000 IU/day, n = 18), 120,000 IU (~4000 IU/day, n = 18), or placebo (n = 17).
Results: There were significant dose- and time-responses of circulating 25(OH)D, 1,25-dihydroxyvitamin D
[1,25(OH)2D], and intact parathyroid hormone (iPTH), but not fibroblast growth factor-23 (FGF-23), phosphorus and
urine calcium to the vitamin D supplements. The mean 25(OH)D concentrations in the 2000 IU and 4000 IU groups
reached ≥30 ng/mL as early as 8-weeks and remained at similar level at 16-weeks. The increase of 25(OH)D was
significantly higher in the 4000 IU group than all the other groups at 8-weeks. The increase of 1,25(OH)2D was
significantly higher in the 2000 IU and 4000 IU groups than the placebo at 8-weeks. Only the 4000 IU compared to
the placebo significantly reduced iPTH at 8- and 16-weeks.
Conclusions: Our RCT, for the first time, comprehensively evaluated time- and dose- responses of vitamin D
supplementation in overweight/obese African Americans with suboptimal vitamin D status. Circulating 25(OH)D,
1,25(OH)2D, and iPTH, but not FGF-23, phosphorus and urine calcium, respond to vitamin D supplementation in
a time- and dose–response manner. By monthly dosing, 2000 IU appears to be sufficient in achieving a 25(OH)D
level of 30 ng/mL in this population. However, importantly, 4000 IU, rather than 2000 IU, seems to suppress iPTH.
If replicated, these data might be informative in optimizing vitamin D status and providing individualized dosing
recommendation in overweight/obese African Americans.
Trial registration: ClinicalTrials.gov number: NCT01583621, Registered on April 3, 2012.
Keywords: Monthly vitamin D, Overweight/obese, African Americans, Dose–response vitamin D, 4000 IU vitamin D
* Correspondence: ydong@gru.edu
1Georgia Prevention Institute, Medical College of Georgia, Georgia Regents
University, Building HS-1640, Augusta 30912-3715, GA, USA
Full list of author information is available at the end of the article
© 2015 Bhagatwala et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bhagatwala et al. BMC Obesity  (2015) 2:27 
DOI 10.1186/s40608-015-0056-2
Background
African Americans as compared to their Caucasian peers
have disproportionately high prevalence of suboptimal
vitamin D status [1–3]. Obesity, a risk factor for poor
vitamin D status, also negatively impacts 25(OH)D re-
sponses to vitamin D supplementation [3–5]. The most
recent Institute of Medicine (IOM) Report identified an
urgent need to conduct randomized clinical trials (RCTs)
of vitamin D supplementation to clarify dose–response
to intake, with a special emphasis on the individuals with
excess adiposity and dark skin pigmentations [6]. Given
the lack of conclusive evidence, the IOM bases its
Recommended Dietary Allowance (RDA) for vitamin D
on bone health, which is 600–800 IU/day corresponding
to a 25(OH)D serum level of ~20 ng/mL [6]. The target
25(OH)D level is ~30 ng/mL recommended by many
other experts for large swaths of the population, although
it is controversial [7–10].
In an earlier placebo-controlled RCT, 208 healthy
postmenopausal African American females residing in
New York (~40.8°N latitude) were given a daily dose
of 800 IU vitamin D plus calcium for two years [11].
The mean 25(OH)D levels remained <30 ng/mL at the
end of the second year, but reached up to 35 ng/mL
within three months after the dose was increased to
2000 IU. However, approximately 40 % of participants
still had 25(OH)D levels between 20–30 ng/mL. The
authors suggested a dose between 2800-4000 IU/day
to optimize vitamin D levels in African Americans,
according to the vitamin D algorithm. Gallagher and col-
leagues [12] supplemented 110 postmenopausal African
American females with suboptimal vitamin D status
living in Nebraska (~41°N latitude) and Indiana (~40°N
latitude) with daily doses between 400–4800 IU vita-
min D plus calcium for 12 months. The authors de-
termined that a daily dose of 1600 IU was required
to achieve the level of 25(OH)D ≥30 ng/mL. In another
study of younger (25–45 years) African American (n = 39)
and Caucasian (n = 90) females living in Nebraska,
400–2400 IU/day vitamin D plus calcium supplements
resulted in a dose and time-responsive increase in
serum 25(OH)D concentrations. The authors estimated
a daily dose between 800–1600 IU in young African
American females, to achieve a level of serum 25(OH)D at
20 ng/mL [12]. More recently, Ng et al., [13] supple-
mented 30–80 years-old 328 African Americans living in
Boston (42°N latitude) with daily 1000, 2000, or 4000 IU
of vitamin D plus calcium for 3 months. It was estimated
that a dose of 1640 IU and 4000 IU vitamin D is desired
to achieve the 25(OH)D concentrations of ≥20 ng/mL and
≥33 ng/mL, respectively. However, dose-responsive RCTs
with exclusive vitamin D supplementation are lacking
in young African Americans, particularly in overweight/
obese individuals.
Circulating 25(OH)D is converted by the enzyme 1-α
hydroxylase to 1,25-dihydroxyvitamin D [1,25(OH)2D],
the active form of vitamin D, which is responsible for the
biological actions on calcium and phosphate homeostasis.
1,25(OH)2D has suppressive effects on parathyroid hor-
mone (PTH) release and the level at which 25(OH)D be-
gins to suppress PTH has been utilized to define vitamin
D sufficiency [14, 15]. Fibroblast growth factor-23 (FGF-
23), a protein secreted from bone, plays a major role in
the regulation of conversion of 25(OH)D to 1,25(OH)2D
by suppressing 1-α hydroxylase. FGF-23 also enhances
the expression of 24-hydroxylase, an enzyme that con-
verts 1,25(OH)2D into a metabolite with much less bio-
logic activity [16, 17]. The major regulators of FGF-23
release are 1,25(OH)2D, phosphate and PTH [18, 19].
However, there is paucity of dose-responsive RCTs evalu-
ating changes of these vitamin D biomarkers to vitamin
D supplementation, particularly in African Americans.
Therefore, the main objective of the current RCT
was to study dose- and time-responses to vitamin D3
supplements of 600 IU/day (current recommended
dietary allowance, RDA), 2000 IU/day (previously the
tolerable upper intake level [UL]) [20] and 4000 IU/day
(the new UL) on circulating 25(OH)D, 1,25(OH)2D, PTH,
FGF-23, phosphorus, and urinary calcium in apparently
healthy young overweight/obese African Americans with
suboptimal vitamin D status residing in Southeastern
United States. The present RCT undertook a monthly
dosage scheme. Monthly dosing that is expected to im-
prove compliance compared to daily dosage is commonly
practiced for vitamin D supplementation [21–23]. How-




In this randomized, double-blinded, placebo-controlled
clinical trial (clinicaltrials.gov registration#: NCT01583621),
participants were recruited from community by advertise-
ments and by word of mouth. Inclusion criteria were self-
reported African American race, age between 13–45 years,
overweight/obese, no pregnancy, no lactation, no known
acute or chronic illnesses, no use of any prescription
medications, birth control pills, herbal, multi-vitamin or
mineral supplementations, and suboptimal vitamin D
status (serum 25(OH)D concentrations of ≤20 ng/mL) [6]
at screening visit. Overweight/obesity was defined by body
mass index (BMI) ≥25 kg/m2 for adults and ≥85th percent-
ile for age and sex for adolescents according to the Center
of Disease Control and Prevention (CDC) criteria. The
study was approved by the institutional review board
(IRB) at the Georgia Regents University (GRU). Adoles-
cents and their guardians provided informed written
assent and consent, respectively; and the adults provided
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informed consent. A total of 129 overweight/obese
African Americans living in Augusta, GA and surround-
ing areas were screened and 70 eligible subjects were
enrolled and followed-up in the between December, 2011
and November, 2012. The trial registration on clinical-
trials.gov was delayed due to an oversight, and the
authors confirm that all ongoing and related trials for this
intervention are registered.
Randomization and vitamin D3 dosing
As presented in Fig. 1, participants were randomly
assigned to either of the following vitamin D supplement
groups: 18,000 IU (equivalent to 600 IU/day), 60,000 IU
(equivalent to 2000 IU/day), 120,000 IU (equivalent to
4000 IU/day) or a placebo for 16 weeks by supervised
monthly dosing. The vitamin D and placebo capsules
were provided by the Bio-Tech Pharmacal, Fayetteville,
AR, and the GRU clinical research pharmacy generated
the randomization codes and dispensed the study capsules.
The GRU clinical pharmacy maintained the randomization
codes until the end of the study and did not have any
direct role in the data collection.
Laboratory tests
Fasting blood samples and spot urine samples were ob-
tained at baseline, 8- and 16-weeks, which were frozen
and stored at −80 °C until assayed. Serum 25(OH)D con-
centrations were measured using enzyme immunoassay
(Immunodiagnostic Systems, Fountain Hills, AZ). The
intra- and inter-assay coefficients of variation (CV) were
5.6 and 6.6 %, respectively. Our laboratory is certified
by the vitamin D external quality assessment scheme
(DEQAS), an international program monitoring accuracy
of 25(OH)D measurements. Plasma 1,25(OH)2D levels
were measured using radioimmunoassay [24]. The intra-
and inter-assay CVs were 9.8 % and 12.6 %, respectively.
Plasma bioactive intact parathyroid hormone (iPTH)
concentrations were measured using an enzyme-linked
immunosorbent assay (ELISA, Immutopics, San Clemente,
CA). Plasma intact FGF-23 concentrations were measured
using ELISA (Immunotopics, Inc., San Clemente, CA).
The intra- and inter-assay CVs were and 6.7 % and 9.8 %,
respectively. Plasma phosphorus was determined using
colorimetric assays kits (Point Scientific, Inc., Canton,
MI). The intra- and inter-assay CVs were 6.4 % and 8.1 %,
respectively. Spot urine calcium levels were measured by
Fig. 1 Randomization scheme and group details (CONSORT 2010 flow chart). 25(OH)D: 25-hydroxyvitamin D
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BioVision’s Colorimetric Calcium Assay Kits. The urine
calcium normalized by urine creatinine (Ca/Cr) was used
to monitor toxicity.
Sample size estimation
Power calculations were computed based on primary out-
comes 25(OH)D, 1,25(OH)2D, iPTH, and FGF-23. The
computations are based upon the linear contrast ap-
proach for the main effect of treatment, rather than the
traditional omnibus F-test followed by post hoc pairwise
comparisons, because a pre-specified contrast condi-
tioned on the ordering of responses is more powerful to
detect the expected pattern, without sacrificing control of
type I error. Required are assumptions concerning the
difference in mean 16-week changes in the response (i.e.,
differences in the mean gain scores) across treatment
arms, and the variance of the gain score, from which
effect size is computed. Using previous data, including
ours, [3, 25, 26] we pooled estimates in standard devi-
ation (SD) of change for 25(OH)D (SD = 5.1 ng/mL),
1,25(OH)2D (SD = 4.0 pg/mL), iPTH (SD = 3.5 pg/mL)
and FGF-23 (SD = 1.2 pg/mL), and we estimated effect
sizes (i.e., Cohen’s d) for these outcomes [25(OH)D,
d = 3.0; 1,25(OH)2D, d = 1.2; iPTH, d = 0.65; and FGF-
23, d = 0.53] based on the assumption that the 600 IU
and 2000 IU groups would have one-quarter and one-
half the mean change, respectively, of that occurring
in the 4000 IU group, relative to the mean change in
the control group. We determined that 10–16 sub-
jects/group would provide 81-96 % power (α = 0.05) to
detect a difference in mean change of the outcome
variable between groups. With a given sample size of
16 subject/group (α-level set at 0.05), the proposed
study will have power of 0.81. Assuming a 10 % sam-
ple size loss due to attrition or insufficient quality of
measurements, a starting sample size of 18 subjects
per group will preserve power of the study design.
Statistical analyses
All statistical analyses were performed using SPSS soft-
ware (IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, version 21.0. Armonk, NY) and statistical
significance was set at P < 0.05. Analysis of variance was
used to compare group differences at baseline for nor-
mally distributed variables or by Kruskal-Wallis test,
otherwise. Differences in proportions were tested by chi-
square test of goodness of fit.
Repeated-measures mixed-models were used with max-
imum likelihood estimation in an intention-to-treat ana-
lysis of each outcome measure using all available data.
Base models for each outcome measure included the
fixed effects of intervention group (placebo, 600 IU/day,
2000 IU/day, or 4000 IU/day) and measurement time
(baseline, 8-weeks, or 16-weeks) and their interaction.
The modeled covariance structure between measurement
periods was unstructured, which used all available mea-
surements on the same subject, including those from
subjects who dropped out of the study. Because signifi-
cant group differences in baseline characteristics were
not detected, covariates were not considered in the
primary analyses. However, secondary analyses were per-
formed to consider potential effects of age, gender,
season, and BMI. The linear contrasts across the four
groups of the change over time tested the dose–response
effects of vitamin D supplementation, and the pairwise
comparisons of changes in the outcome variables be-
tween groups were performed.
Results
Baseline clinical characteristics
Table 1 displays the baseline characteristics of the partic-
ipants. Of 129 screened, ~75 % (96 individuals) met the
inclusion criteria. A total of 70 subjects were available at
baseline. The baseline serum 25(OH)D in the entire
sample was 14.77 ± 0.6 ng/mL. Age, gender distribution,
BMI, serum 25(OH)D, plasma iPTH, 1,25(OH)2D, FGF-
23 and phosphorus did not differ among the groups at
baseline. No side effects were observed during the study
period. A total of 5 participants discontinued the study
either due to loss of follow up (2 subjects), positive preg-
nancy test (2 subjects) or diagnosis of diabetes (1
subject).
25 (OH)D: dose and time responses at 8- and 16-weeks
There were overall group by time interactions (P < 0.01),
suggesting dose- and time-dependent increases in serum
25(OH)D concentrations to the monthly vitamin D sup-
plements (Fig. 2). In the 600 IU group, mean 25(OH)D
concentrations remained ~20 ng/mL both at 8- (21.0 ±
1.0 ng/mL) and 16-weeks (22.61 ± 1.24 ng/mL). On the
other hand, both 2000 IU and 4000 IU vitamin D groups
raised mean 25(OH)D concentrations to the level of
30 ng/mL at 8-weeks (30.50 ± 2.1 and 35.66 ± 3.4 ng/mL,
respectively), and maintained at a similar level (36.01 ±
3.1 and 34.80 ± 2.4 ng/mL, respectively) at 16-weeks.
In post-hoc group-wise comparison, the changes in
25(OH)D concentrations from baseline to 8-weeks in
the 4000 IU group (22.41 ± 1.8 ng/mL) were signifi-
cantly greater compared to the 2000 IU (14.56 ± 1.8 ng/
mL, p < 0.01), 600 IU (7.06 ± 2.0 ng/mL, p < 0.01) and
placebo (0.12 ± 1.9 ng/mL, p < 0.01) groups. At 16-weeks,
however, the changes in 25(OH)D concentrations in the
4000 IU group plateaued and were similar to the changes
in the 2000 IU group (21.51 ± 2.0 vs. 20.08 ± 2.0 ng/mL,
p = 0.60). Within the 4000 IU group, 25(OH)D concen-
trations at 16-weeks did not differ from those at 8-weeks
(34.77 ± 2.5 vs. 35.66 ± 3.4 ng/mL, p = 0.60). However,
within the 2000 IU group, 25(OH)D concentrations at
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16-weeks were significantly higher than those at 8-weeks
(36.01 ± 3.1 vs. 30.50 ± 2.1 ng/mL, p = 0.02).
1,25 (OH)2D: dose and time responses at 8- and 16-weeks
There were overall group by time interactions (P = 0.046),
suggesting dose- and time-dependent increases in plasma
1,25(OH)2D concentrations to the monthly vitamin D
supplements (Fig. 3). In post-hoc group-wise comparisons,
the changes from baseline to 8-weeks, but not the changes
from baseline to 16-weeks, were significantly higher both
in the 4000 IU and 2000 IU groups versus the placebo
group. However, only the 4000 IU group showed a greater
increase than the 600 IU group (8.89 ± 2.0 pg/mL vs.
2.95 ± 2.1 pg/mL, p = 0.04) at 8-weeks. The increases of
1,25(OH)2D concentrations at 16-weeks in the 4000 IU
group versus the placebo or 600 IU group was marginally
significant (p = 0.07 and 0.08, respectively). Nevertheless,
the increases of 1,25(OH)2D in the 600 IU group were not
statistically significant either at 8- or 16-weeks.
PTH: dose and time responses at 8- and 16-weeks
There were overall group by time interactions (p =
























P < 0.01 for trend
Fig. 2 Dose- and time-responses of 25(OH)D. Intention-to-treat
mixed-model repeated-measures analysis of variance of the effect of
group on serum 25-hydroxyvitamin D [25(OH)D], the P-value in each
panel indicates the test of the dose–response trend. Error bars indicate




























P = 0.046 for trend
Fig. 3 Dose- and time-responses of 1,25(OH)2D. Intention-to-treat
mixed-model repeated-measures analysis of variance of the effect of
group on plasma 1,25-dihydroxyvitamin D [1,25(OH)2D], the P-value
in each panel indicates the test of the dose–response trend. Error
bars indicate 95 % confidence intervals
Table 1 Baseline clinical characteristics
Variable Study groups P-value
Placebo (n = 17) 600 IU/day (n = 17) 2000 IU/day (n = 18) 4000 IU/day (n = 18)
Age (years) 27.78 ± 2.6 26.19 ± 2.5 24.38 ± 2.0 25.51 ± 2.2 0.77
Male/Femalea 4/12 2/13 3/14 2/15 0.76
Height (cm) 164.28 ± 2.1 164.60 ± 2.0 163.84 ± 2.4 164.20 ± 1.7 0.99
Weight (kg) 98.42 ± 6.7 93.39 ± 3.7 99.16 ± 5.0 92.77 ± 4.8 0.74
BMI (kg/m2) 36.19 ± 2.0 34.56 ± 1.4 37.08 ± 1.9 34.42 ± 1.7 0.66
Serum 25(OH)D (ng/mL) 15.88 ± 1.4 14.00 ± 0.8 15.93 ± 1.0 13.25 ± 1.0 0.21
Plasma iPTH (pg/mL)# 47.32 ± 3.6 59.60 ± 7.8 50.60 ± 4.2 62.00 ± 8.8 0.32
Plasma 1,25(OH)2D (pg/mL) 34.04 ± 1.9 37.40 ± 1.8 35.18 ± 2.3 32.70 ± 1.1 0.46
Plasma FGF-23 (pg/mL)# 6.53 ± 0.9 6.92 ± 0.8 8.57 ± 1.6 6.57 ± 0.9 0.81
Plasma Phosphorus (mg/dL)# 3.74 ± 0.2 4.01 ± 0.3 3.61 ± 0.1 3.80 ± 0.1 0.71
Urine Ca/Cr ratio 0.08 ± 0.05 0.05 ± 0.03 0.10 ± 0.05 0.08 ± 0.05 0.09
Values are presented as mean ± s.e.m
BMI Body mass index, 25(OH)D Serum 25-hydroxyvitamin D, Plasma 1,25(OH)2D 1,25-dihydroxyvitamin D, iPTH Intact parathyroid hormone, FGF-23 Fibroblast
Growth Factor-23, Ca/Cr Calcium/creatinine ratio
aGroup differences analyzed using chi-square test
#Group differences analyzed using Kruskal-Wallis test
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in plasma iPTH concentrations to the monthly vitamin
D supplements (Fig. 4). A post-hoc group-wise compari-
son showed that iPTH concentrations reduced signifi-
cantly from baseline only in the 4000 IU group, rather
than the 600 or 2000 IU group, both at 8-weeks and 16-
weeks (p < 0.05), as compared to the placebo group. The
changes did not differ among the other groups either at
8- or 16-weeks.
Plasma FGF-23, phosphorus and urine Ca/Cr ratio: dose
and time responses at 8- and 16-weeks
There were not significant overall group by time in-
teractions in FGF-23, phosphorus, and urine Ca/Cr
ratio either at 8- or 16-weeks (all p > 0.05).
Discussion
To our knowledge, this is the first dose–response vita-
min D supplementation RCT comprehensively evaluat-
ing vitamin D responses in overweight/obese African
Americans with suboptimal vitamin D status. Our major
findings include: 1) vitamin D3 supplements by monthly
dosing increased circulating 25(OH)D and 1,25(OH)D;
and suppressed iPTH in a time- and dose-dependent
manner; 2) both 2000 IU/day and 4000 IU/day, rather
than 600 IU/day, achieved the 25(OH)D level of 30 ng/
mL. Although 4000 IU/day was not superior to 2000 IU/
day in increasing 25(OH)D concentrations, 4000 IU/day
increased 25(OH)D concentrations more rapidly than
2000 IU/day by monthly dosing; 3) Perhaps more import-
antly, only 4000 IU/day suppressed iPTH; and 4) plasma
FGF-23, phosphorus and urine calcium did not change in
time- or dose- dependent manner.
25(OH)D
Only few RCTs have studied dose-responsiveness to
vitamin D supplementation in African Americans. We
report for the first time that monthly vitamin D3 raises
serum 25(OH)D concentrations in a dose- and time-
dependent manner in overweight/obese African Americans
with suboptimal vitamin D status as defined by serum
25(OH)D level ≤ 20 ng/mL [6]. By monthly dosing, 2000 IU
and 4000 IU vitamin D, rather than 600 IU, are both effi-
cient in optimizing vitamin D status over 16 weeks. Of
note, the current RDA of 600 IU/day is not well stud-
ied in African Americans. Previous dose–response trial
in nursing home residents in Boston [27] reported that
600 IU/day vitamin D may not be adequate in achiev-
ing a 25(OHD) level of 30 ng/mL. In the elderly living in
the Netherlands with suboptimal vitamin D status, a dose
of 600 IU/day did not achieve the level of 30 ng/mL either
by daily, weekly or monthly dosing after ~4 months [28].
One of the most interesting findings of our study was
that the 25(OH)D concentrations at posttest between
the 4000 IU and 2000 IU groups did not differ. The
mean 25(OH)D concentrations in the 4000 IU group
seemed to plateau and become similar to the 25(OH)D
concentrations in the 2000 IU group. In the dose–re-
sponse trial by Gallagher in post-menopausal Caucasian
females with 25(OH)D concentrations below 20 ng/mL,
[29] the 25(OH)D concentrations increased in a quad-
ratic, rather than a linear pattern with an increasing
vitamin D dose from 400–4800 IU/day. The 25(OH)D
concentrations in their study began to plateau at the
dose of ~4000 IU. In a subset of African Americans [12],
the dose–response curves for 25(OH)D concentrations
were linear. The authors speculated that the observed
racial differences could be due to a very small number of
African Americans in the 3200 and 4000 IU groups. There
are few dose–response RCTs comparing 2000 IU and
4000 IU doses. Pregnant Arab females with vitamin D
deficiency were previously supplemented with 400, 2000,
or 4000 IU/day [30]. The 25(OH)D responses in the 2000
and the 4000 IU groups paralleled from 12–16 weeks of
gestation (baseline) to 28 weeks of gestation (~16 weeks),
as observed in our study. Heaney and colleagues [31]
suggest that at a lower concentration of 25(OH)D, the
conversion of vitamin D3 from oral or cutaneous intake
into 25(OH)D follows first-order kinetics, which later
switches to a slower, zero-order with saturation of hepatic
25-hydroxylase and the 25(OH)D levels start to plateau.
The serum 25(OH)D concentration at which this change
occurs was calculated to be ~35.2 ng/mL. In our study,
the 4000 IU group by monthly dosing achieved mean
serum 25(OH)D concentrations of 35.66 ± 3.4 ng/mL as
early as 8-weeks, making it plausible that the rate of
conversion into 25(OH)D might have diminished from 8-























Plasma intact parathyroid hormone
P = 0.042 for trend
Fig. 4 Dose- and time-responses of iPTH. Intention-to-treat mixed-
model repeated-measures analysis of variance of the effect of group
on plasma intact parathyroid hormone (iPTH), the P-value in each
panel indicates the test of the dose–response trend. Error bars indicate
95 % confidence intervals
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mean serum 25(OH)D concentrations of 30.50 ± 2.1 ng/
mL at 8-weeks and continued to increase to 16-weeks.
Our data indicate that a dose of 2000 IU by monthly dos-
ing may be appropriate to improve the vitamin D status
up to the level of 30 ng/mL, but 4000 IU can achieve it
more rapidly.
1,25(OH)2D
We demonstrated dose- and time-dependent increases
in 1,25(OH)2D concentrations, and 1,25(OH)2D concen-
trations can be raised by 2000 or 4000 IU in a monthly
dosing as early as 8 weeks. Provided the continuous
increase of 1,25(OH)2D concentrations at 16-weeks by
4000 IU in the present study, though marginally signifi-
cant, future RCTs with a larger sample size are war-
ranted. To the best of our knowledge, there was only
one previous study evaluating the dose-responsiveness of
1,25(OH)2D to vitamin D supplementation, in which no
significant dose-dependent increases in 1,25(OH)2D were
observed in a population of African American and Cau-
casian children with daily doses ranging from 400 to
4000 IU of vitamin D supplements for 12 weeks [32].
The disparities of the findings could be due to the differ-
ences in the baseline 25(OH)D levels or the frequency of
dosing.
iPTH
We observed dose- and time-responsive reductions in
plasma iPTH concentrations, whereas mixed results in this
regard have been reported in the literature [12, 29, 32].
The present study demonstrated that 4000 IU, rather
than 600 or 2000 IU by monthly dosing, significantly
reduced iPTH at 8- and 16-weeks. Our group previ-
ously reported that iPTH concentrations in response
to 2000 IU/day was unchanged in African American
adolescents [3] and adults [26], which is in agreement
with the findings of others [33]. These findings may
reinforce it that a dose higher than 2000 IU/day would be
required to suppress iPTH. However, a higher daily
vitamin D dose, i.e., ~5000 IU/day, modestly yet insig-
nificantly reduced iPTH, as compared to 1000 and
2000 IU/day, respectively [33, 34]. Thus, our results
might indicate the superiority of monthly dosing in
suppressing iPTH.
FGF-23 and phosphorus
To the best of our knowledge, our study is among the
few to report FGF-23 and phosphorus in apparently
healthy African Americans, and the first to study the
dose-responsiveness to vitamin D supplementation. Of
note, baseline plasma intact FGF-23 levels in our African
American subjects were lower than previously reported
[35, 36]. We did not observe any dose- or time-
dependent changes in either FGF-23 or phosphorus.
Eighteen otherwise healthy premenopausal Turkish fe-
males with serum 25(OH)D concentrations below 30 ng/
mL were previously given a loading dose of 150,000 IU
vitamin D3 followed by daily 880 IU plus 1000 mg cal-
cium for 6 weeks [25]. At posttest, significant reductions
in FGF-23 and phosphorus were observed. Another study
by Turner and colleagues in 45 osteoporotic older males
and females with serum 25(OH)D concentrations below
20 ng/mL administered a single loading dose of
300,000 IU vitamin D2 intramuscular followed by daily
800 IU of vitamin D3 plus 1200 mg calcium orally for
3 months [37]. Significant increases were observed in
FGF-23 and phosphorus at 1, 2, and 3 months. By supple-
menting weekly 50,000 IU vitamin D2 plus calcium in
individuals between 18–45 years of age with serum
25(OH)D levels below 20 ng/mL, Burnett-Bowie and
colleagues reported a significant increase in FGF-23 with
no changes in phosphate concentrations after 8- and 12-
weeks [38]. Thus, FGF-23 and phosphate changes in
response to vitamin D supplementation are inconsistent.
All these observed discrepancies could be due to, 1) the
various dosing regimens; or 2) the differences in assay
methods, e.g., intact FGF-23 versus c-terminal FGF-23;
or 3) the use of calcium with vitamin D supplementation;
or 4) low baseline FGF-23 levels in our study. We also
speculate that in our study the changes of the two stimu-
lants for FGF-23, i.e. the reductions in iPTH and in-
creases in 1,25(OH)2D, might have kept the FGF-23
concentrations unchanged. Last, the control of circulat-
ing concentrations of FGF-23 is a complex matter, and
monthly versus daily dosing may result in fluctuations in
the concentrations of circulating FGF-23 [39].
Strengths and limitations
There are several strengths in the present study. We
exclusively recruited overweight/obese African American
participants with suboptimal vitamin D status. We
comprehensively analyzed various vitamin D related
biomarkers, and administered vitamin D supplements
without calcium supplements. The doses selected in this
study were based on the current RDA and UL by the
IOM, [6] and monthly supervised dosing scheme was
undertaken to ensure 100 % compliance. Although
monthly vitamin D dosing has been previously adminis-
tered, our study is the first to use a dose–response
design. The limitations of our study are worth mention-
ing. First, the bioavailability of 25(OH)D was not included
in the current study, although we only supplemented
African Americans [40]. Second, the participants were
recruited in different seasons. However, only individuals
with suboptimal vitamin D status were recruited irre-
spective of the season of enrollment, and the results did
not alter after adjusting for seasons. Third, the female
representation was higher in our sample compared to
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males. However, the gender distribution was not different
among groups, and the results did not differ after adjust-
ing for gender as a potential confounder. Fourth, the
objective of the current study is to study a panel of circu-
lating vitamin D biomarkers in response to vitamin D
supplementation. Skeletal and extra-skeletal functional
outcomes, that are not part of this study, would deserve
investigations in the future, to help to select doses and
time scheme. Finally, the sample size in each group was
relatively small, which emphasizes the need for larger
studies.
Conclusions
In summary, circulating 25(OH)D, 1,25(OH)2D, and
iPTH concentrations, but not FGF-23, phosphorus and
urine calcium, respond to monthly vitamin D supple-
mentation in a time- and dose-dependent manner. Both
2000 IU and 4000 IU vitamin D in monthly dosing
appear to be comparable and effective in achieving the
25(OH)D level of 30 ng/mL, but 4000 IU optimizes vita-
min D status more rapidly. In monthly dosing, 4000 IU
suppresses iPTH rapidly, and the suppression seems to
sustain over time. The biological benefits of 4000 IU
vitamin D needs to be further investigated in well-
designed, larger RCTs with skeletal and extra-skeletal
outcomes.
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